For many people, the 14-15% average weight loss with semaglutide, combined with its better tolerability profile, represents the right balance of benefit and risk
The clinical data is overwhelming
Much more work is ahead, but the scientists see potential for this microbe, Eubacterium limosum, to be used for therapeutic purposes in the future
EncircleRx: Cardiodiabesity gives clients optionality and predictability in managing cardiodiabesityobesity, diabetes and cardiovascular diseasewith the first-ever GLP-1 financial guarantee from a PBM
Develop, demonstrate, and disseminate learning modules for school personnel (teachers, coaches), parents, school-aged children, and primary care pediatricians and child mental health professionals about the GL1-RA medications, their appropriate uses and possible abuse